RT Journal Article
T1 Rare indications for a lung transplant. A European Society of Thoracic Surgeons survey.
A1 Nosotti, Mario
A1 D'Ovidio, Frank
A1 Leiva-Juarez, Miguel
A1 Keshavjee, Shaf
A1 Rackauskas, Mindaugas
A1 Van Raemdonck, Dirk
A1 Ceulemans, Laurens J
A1 Krueger, Thorsten
A1 Koutsokera, Angela
A1 Schiavon, Marco
A1 Rea, Federico
A1 Iskender, Ilker
A1 Moreno, Paula
A1 Alvarez, Antonio
A1 Luzzi, Luca
A1 Paladini, Piero
A1 Rosso, Lorenzo
A1 Bertani, Alessandro
A1 Venuta, Federico
A1 Pecoraro, Ylenia
A1 Al-Kattan, Khaled
A1 Kubisa, Bartosz
A1 Inci, Ilhan
K1 Lung diseases
K1 Lung transplant
K1 Rare diseases
K1 Respiratory insufficiency
AB The European Society of Thoracic Surgeons Lung Transplantation Working Group promoted a survey to evaluate overall survival in a large cohort of patients receiving lung transplants for rare pulmonary diseases. We conducted a retrospective multicentre study. The primary end point was overall survival; secondary end points were survival of patients with the most common diagnoses in the context of rare pulmonary diseases and chronic lung allograft dysfunction (CLAD)-free survival. Finally, we analysed risk factors for overall survival and CLAD-free survival. Clinical records of 674 patients were extracted and collected from 13 lung transplant centres; diagnoses included 46 rare pulmonary diseases. Patients were followed for a median of 3.1 years. The median survival after a lung transplant was 8.5 years. The median CLAD-free survival was 8 years. The multivariable analysis for mortality identified CLAD as a strong negative predictor [hazard ratio (HR) 6.73)], whereas induction therapy was a protective factor (HR 0.68). The multivariable analysis for CLAD occurrence identified induction therapy as a protective factor (HR 0.51). When we stratified patients by CLAD occurrence in a Kaplan-Meier plot, the survival curves diverged significantly (log-rank test: P  We observed that overall survival and CLAD-free survival were excellent. We support the practice of allocating lungs to patients with rare pulmonary diseases because a lung transplant is both effective and ethically acceptable.
YR 2020
FD 2020
LK http://hdl.handle.net/10668/16423
UL http://hdl.handle.net/10668/16423
LA en
DS RISalud
RD Apr 7, 2025